AXSM

About AXSM

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is developing novel therapies for central nervous system (CNS) disorders for which there are limited treatment options. It is developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. The Company's CNS portfolio includes four product candidates, such as AXS-05, AXS-07, AXS-12, and AXS-14. AXS-05 is being developed for the treatment of major depressive disorder (MDD), Alzheimer's disease agitation (AD agitation), and smoking cessation. AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine. AXS-12 is an investigational medicine in development for the treatment of narcolepsy. The Company also provides Sunosi, which is dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients.